ADMA Biologics
ADMA
356 hedge funds and large institutions have $4.02B invested in ADMA Biologics in 2025 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 140 increasing their positions, 119 reducing their positions, and 61 closing their positions.
84% more call options, than puts
Call options by funds: $68.1M | Put options by funds: $37M
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
23% more capital invested
Capital invested by funds: $3.28B → $4.02B (+$739M)
18% more repeat investments, than reductions
Existing positions increased: 140 | Existing positions reduced: 119
0.68% more ownership
Funds ownership: 91.91% → 92.59% (+0.68%)
3% less first-time investments, than exits
New positions opened: 59 | Existing positions closed: 61
2% less funds holding
Funds holding: 365 → 356 (-9)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$64.7M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$57M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$43.5M |
| 4 |
SHCM
Sachem Head Capital Management
New York
|
+$40.7M |
| 5 |
Fundsmith LLP
London,
United Kingdom
|
+$35.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oberweis Asset Management
Lisle,
Illinois
|
-$39.8M |
| 2 |
PL
Perpetual Ltd
Sydney, New South Wales,
Australia
|
-$31.1M |
| 3 |
Goldman Sachs
New York
|
-$31M |
| 4 |
Renaissance Technologies
New York
|
-$20.9M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$20.8M |
ADMA Hedge Fund Activity: Q4 2025 in Review
356 of the 8,266 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q4 2025, worth a combined $4.02B — up 23% from $3.28B a quarter earlier.
Sellers outnumbered buyers: 61 funds closed out of ADMA and 59 opened new positions — a net loss of 2 holders — while 119 trimmed existing stakes and 140 added.
The largest buyer was Janus Henderson Group, adding an estimated $64.7M. The largest seller was Oberweis Asset Management, exiting entirely with an estimated $39.8M sold.
- 356 institutional investors held ADMA Biologics (ADMA) as of Q4 2025, down from 365 in Q3 2025.
- Funds reported $4.02B of ADMA Biologics stock for Q4 2025, up 23% quarter-over-quarter.
- 59 funds opened new ADMA Biologics positions in Q4 2025 and 61 closed out, a net change of -2 holders.
- The largest ADMA Biologics buyer in Q4 2025 was Janus Henderson Group, an estimated $64.7M added.
- The largest ADMA Biologics seller in Q4 2025 was Oberweis Asset Management, an estimated $39.8M sold.
Based on aggregated 13F filings for Q4 2025.